Patents by Inventor David Buttar

David Buttar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolopyrimidine compounds and their use in treating cancer
    Patent number: 12503473
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Grant
    Filed: November 14, 2023
    Date of Patent: December 23, 2025
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting, Gillian McGregor Lamont, David Buttar, Jason Grant Kettle
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER
    Publication number: 20240217980
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Application
    Filed: November 14, 2023
    Publication date: July 4, 2024
    Inventors: Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING, Gillian McGregor LAMONT, David BUTTAR, Jason Grant KETTLE
  • Triazolopyrimidine compounds and their use in treating cancer
    Patent number: 11851432
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Grant
    Filed: July 5, 2021
    Date of Patent: December 26, 2023
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting, Gillian McGregor Lamont, David Buttar, Jason Grant Kettle
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER
    Publication number: 20210340150
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Application
    Filed: July 5, 2021
    Publication date: November 4, 2021
    Inventors: Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING, Gillian McGregor LAMONT, David BUTTAR, Jason Grant KETTLE
  • Triazolopyrimidine compounds and their use in treating cancer
    Patent number: 11084827
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: August 10, 2021
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting, Gillian McGregor Lamont, David Buttar, Jason Grant Kettle
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER
    Publication number: 20210087196
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 25, 2021
    Inventors: Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING, Gillian McGregor LAMONT, David BUTTAR, Jason Grant KETTLE
  • Compounds
    Patent number: 10301267
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • CHEMICAL COMPOUNDS
    Publication number: 20190038607
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 7, 2019
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical compounds
    Patent number: 10130617
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: November 20, 2018
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • CHEMICAL COMPOUNDS
    Publication number: 20170326115
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: February 28, 2017
    Publication date: November 16, 2017
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • NOVEL COMPOUNDS
    Publication number: 20170260143
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • Methods of treating cancer with a pyrazole derivative
    Patent number: 9688640
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: June 27, 2017
    Assignee: ASTRAZENECA AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • Chemical compounds
    Patent number: 9616050
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: April 11, 2017
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Chemical Compounds
    Publication number: 20160136140
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: August 31, 2015
    Publication date: May 19, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • NOVEL COMPOUNDS
    Publication number: 20150299134
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: October 22, 2015
    Applicant: AstraZeneca AB
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • Chemical compounds
    Patent number: 9155727
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: October 13, 2015
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Marie Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • CHEMICAL COMPOUNDS
    Publication number: 20140357661
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh BRADBURY, David BUTTAR, Christopher DE SAVI, Craig Samuel DONALD, Richard Albert NORMAN, Alfred Arthur RABOW, Gordon Stuart CURRIE, Heather Marie REDFEARN, Nadim AKHTAR, Helen Elizabeth WILLIAMS, Matthew OSBORNE, Neda YAVARI
  • NOVEL COMPOUNDS
    Publication number: 20140066455
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 6, 2014
    Applicant: AstraZeneca AB
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
    Patent number: 8604022
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: December 10, 2013
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas, David Buttar
  • N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF
    Publication number: 20120129844
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 24, 2012
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas